The U.S. Supreme Court has been chipping away at the power of administrative agencies in recent years. In a pair of significant cases at the Court this year, Loper Bright Enterprises v. Raimondo and Relentless Inc. v. Department of Commerce, the Supreme Court is widely expected to overturn or narrow the long-standing practice (called “Chevron” deference) of courts deferring to reasonable agency rulemakings. This panel will explore the profound impact the loss of Chevron deference could have on the life sciences industry. The panel will also discuss the challenges to FDA’s decades-old approval of the abortion drug mifepristone, which raises numerous questions about the scope of FDA’s authority and the extent to which courts will defer to scientific expertise. Lastly, the panel will explore how these cases could impact investment decisions, R&D efforts, and the competitive marketplace, as well as steps the industry could take in the aftermath.